FTC Claims Revived Over Teva-AbbVie 'Pay For Delay' Deal
AndroGel $448M Pay-For-Delay Disgorgement Spiked On Appeal
AbbVie and FTC both see wins and setbacks in Third Circuit ruling on case involving reverse-payment patent settlement with Teva.
AbbVie and FTC both see wins and setbacks in Third Circuit ruling on case involving reverse-payment patent settlement with Teva.